Oxy 210
Alternative Names: Oxy-210Latest Information Update: 28 Oct 2024
At a glance
- Originator MAX BioPharma
- Developer MAX BioPharma; National Institute of Infectious Diseases
- Class Antifibrotics; Antineoplastics; Antivirals; Hepatoprotectants; Small molecules; Sterols
- Mechanism of Action Hedgehog cell signalling pathway inhibitors; Transforming growth factor beta inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections; Non-alcoholic steatohepatitis
- No development reported Cancer
Most Recent Events
- 28 Oct 2024 Oxy 210 is still in preclinical trials for Non-alcoholic steatohepatitis in the US (MAX BioPharma pipeline October 2024)
- 24 Oct 2024 MAX BioPharma announces intention to submit IND to US FDA for Non-alcoholic steatohepatitis
- 24 Oct 2024 Pharmacodynamic data from a preclinical study in Non-alcoholic steatohepatitis released by MAX BioPharma